Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Gains from Investment Securities (2022 - 2025)

CervoMed (CRVO) has disclosed Gains from Investment Securities for 6 consecutive years, with $466600.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 26.73% to $466600.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $466600.0 through Dec 2025, down 26.73% year-over-year, with the annual reading at $466600.0 for FY2025, 26.73% down from the prior year.
  • Gains from Investment Securities hit $466600.0 in Q4 2025 for CervoMed, down from $995374.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $995374.0 in Q3 2025 to a low of $51.0 in Q1 2024.
  • Historically, Gains from Investment Securities has averaged $254736.5 across 4 years, with a median of $142566.0 in 2022.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 75.52% in 2024 and later soared 534801.96% in 2025.
  • Year by year, Gains from Investment Securities stood at $349374.0 in 2022, then changed by 0.0% to $349374.0 in 2023, then skyrocketed by 82.27% to $636802.0 in 2024, then decreased by 26.73% to $466600.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for CRVO at $466600.0 in Q4 2025, $995374.0 in Q3 2025, and $54000.0 in Q2 2025.